Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies | Circulation
Difference in restricted mean survival time estimated using the Pooled... | Download Scientific Diagram
Efficacy and Safety of Intensive Blood Pressure Therapy Using Restricted Mean Survival Time—Insights from the SPRINT Trial - The American Journal of Medicine
A) Kaplan-Meier Curves and Restricted Mean Survival Time (RMST) for... | Download Scientific Diagram
A) Kaplan-Meier Curves and Restricted Mean Survival Time (RMST) for... | Download Scientific Diagram
Novel Risk Modeling Approach of Atrial Fibrillation With Restricted Mean Survival Times | Circulation: Cardiovascular Quality and Outcomes
Difference in restricted mean survival time and ICER according to the... | Download Table
Kaplan-Meier survival analysis
Biostatistics short course: Survival Analysis Based on the Restricted Mean Survival Time – An Alternative to the Proportional Hazards Model – December 10 - Harvard Catalyst
Analyzing Customer Churn - Restricted Mean Survival Time
cox model - Restricted Mean Survival Time vs Hazard Ratio - How to describe the differences? - Cross Validated
Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the Week - ScienceDirect
Long-term adult congenital heart disease survival after heart transplantation: A restricted mean survival time analysis - The Journal of Heart and Lung Transplantation
Restricted mean survival time (RMST) in the 2 groups after (A) 1: 1... | Download Scientific Diagram
Restricted mean survival time (RMST) as the area under the curve. (A)... | Download Scientific Diagram
Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer - Annals of Oncology
The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt - Royston - 2011 - Statistics in Medicine - Wiley Online Library
Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation - ScienceDirect
Kaplan-Meier based methods to address non-proportional hazard issues Bo Huang, PhD Joint Statistical Meetings 29 July, 2018 Vancouver, BC. - ppt download
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome | BMC Medical Research Methodology | Full Text
The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt - Royston - 2011 - Statistics in Medicine - Wiley Online Library
Novel Risk Modeling Approach of Atrial Fibrillation With Restricted Mean Survival Times | Circulation: Cardiovascular Quality and Outcomes
Estimating restricted mean survival time and expected life-years lost in the presence of competing risks within flexible parametric survival models | BMC Medical Research Methodology | Full Text
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome | BMC Medical Research Methodology | Full Text
PLOS ONE: Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study
Adjusted restricted mean survival times in observational studies - Conner - 2019 - Statistics in Medicine - Wiley Online Library
![PDF] Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/3e44c5c7f36a8a9cef47c5c948c038c62cc29280/4-Figure1-1.png "PDF] Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development. | Semantic Scholar")
PDF] Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development. | Semantic Scholar
Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards | The BMJ
